+

WO2009114040A3 - Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations - Google Patents

Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations Download PDF

Info

Publication number
WO2009114040A3
WO2009114040A3 PCT/US2008/077839 US2008077839W WO2009114040A3 WO 2009114040 A3 WO2009114040 A3 WO 2009114040A3 US 2008077839 W US2008077839 W US 2008077839W WO 2009114040 A3 WO2009114040 A3 WO 2009114040A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
methods
compositions
epitopes
antibodies
Prior art date
Application number
PCT/US2008/077839
Other languages
English (en)
Other versions
WO2009114040A2 (fr
Inventor
Paul Dal Monte
Jill Giles-Komar
George Heavner
David Knight
Mehrnaz Khossravi
Jeffrey Luo
David Shealy
David Volkin
Original Assignee
Centocor Ortho Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc. filed Critical Centocor Ortho Biotech Inc.
Priority to EP08873207A priority Critical patent/EP2205276A4/fr
Publication of WO2009114040A2 publication Critical patent/WO2009114040A2/fr
Publication of WO2009114040A3 publication Critical patent/WO2009114040A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps anti-IL-12/23p40 qui se lie à une partie de la protéine IL-12 ou IL-23 correspondant à la sous-unité P40 de IL-12 ou IL-23, des compositions, formulations le contenant, et des procédés d'administration, qui ont des applications dans des utilisations et dispositifs de diagnostic et/ou thérapeutiques.
PCT/US2008/077839 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations WO2009114040A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08873207A EP2205276A4 (fr) 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28
US60/975,997 2007-09-28

Publications (2)

Publication Number Publication Date
WO2009114040A2 WO2009114040A2 (fr) 2009-09-17
WO2009114040A3 true WO2009114040A3 (fr) 2010-05-27

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/077839 WO2009114040A2 (fr) 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations

Country Status (9)

Country Link
US (1) US20090181027A1 (fr)
EP (1) EP2205276A4 (fr)
CR (1) CR11399A (fr)
EC (1) ECSP10010056A (fr)
GT (1) GT201000073A (fr)
HN (1) HN2010000573A (fr)
NI (1) NI201000042A (fr)
SV (1) SV2010003517A (fr)
WO (1) WO2009114040A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013136908A (ru) * 2011-01-07 2015-02-20 Эббви Инк. Антитела kil-12/il-23 и их применение
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JP2020500152A (ja) * 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
KR102692727B1 (ko) 2017-03-31 2024-08-08 메이지 세이카 파루마 가부시키가이샤 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (fr) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Formulations liquides stables, à faible viscosité et à haute concentration en un anticorps anti-il-12/23p40
EP3793521A4 (fr) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
CN113164596A (zh) 2018-09-24 2021-07-23 詹森生物科技公司 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CA3138241A1 (fr) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Methode de traitement de maladie intestinale inflammatoire au moyen d'une polytherapie d'anticorps diriges contre il -23 et tnf alpha
JP7638955B2 (ja) * 2019-07-30 2025-03-04 中山康方生物医▲藥▼有限公司 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
WO2021161270A2 (fr) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il-12/il23
US12258393B2 (en) 2020-05-21 2025-03-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN115856281A (zh) * 2022-12-02 2023-03-28 北京世纪沃德生物科技有限公司 基于胶乳免疫比浊法测定il-12的试剂盒及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214293A1 (en) * 2000-08-07 2005-09-29 Jill Giles-Komar ANTI-IL-12 antibodies and compositions
WO2006096488A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps en plateau

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2796140A1 (fr) * 1999-03-25 2000-09-28 Jochen Salfeld Anticorps humains de liaison de l'il-12 humaine et methodes de production connexes
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
TWI406943B (zh) * 2004-12-21 2013-09-01 Centocor Inc 抗-ｉｌ-１２抗體、抗原決定部位、組成物、方法及用途
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
WO2007002543A2 (fr) * 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214293A1 (en) * 2000-08-07 2005-09-29 Jill Giles-Komar ANTI-IL-12 antibodies and compositions
WO2006096488A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps en plateau

Also Published As

Publication number Publication date
WO2009114040A2 (fr) 2009-09-17
CR11399A (es) 2010-08-18
US20090181027A1 (en) 2009-07-16
EP2205276A2 (fr) 2010-07-14
NI201000042A (es) 2010-09-13
ECSP10010056A (es) 2010-04-30
SV2010003517A (es) 2010-08-10
EP2205276A4 (fr) 2012-08-15
GT201000073A (es) 2012-04-19
HN2010000573A (es) 2012-12-10

Similar Documents

Publication Publication Date Title
WO2009114040A3 (fr) Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
IL178838A (en) Antibodies that specifically bind to human p-psgl-1 and p-selectin, pharmacological preparations containing such antibody, and momentary acids and their encoded vectors
WO2008021076A3 (fr) Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2009140348A3 (fr) Anticorps anti-il-6/il-6r et procédés d'utilisation
WO2008118587A3 (fr) Applications thérapeutiques des cellules présentant un antigène humain par l'intermédiaire de la dectine.-1
EP2570137A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (DEC-205)
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2012032181A3 (fr) Nouveaux dérivés d'anticorps
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
WO2008121615A3 (fr) Formulation d'anticorps
MY157772A (en) Antibody formulation
WO2007106744A3 (fr) Anticorps anti-5t4 et leurs utilisations
WO2011157741A3 (fr) Conjugués anticorps humain-médicament contre le facteur tissulaire
WO2009136286A3 (fr) Anticorps à réaction croisée anti-il-17a/il-17f et leurs procédés d'utilisation
EP2402373A3 (fr) Anticorps anti-EphB4 et procédés d'utilisation associés
WO2009055711A3 (fr) Anticorps de protéine g anti-rsv
EP2371388A3 (fr) Formulations d'anticorps
EP3210625A3 (fr) Les peptides thérapeutiques comprenant la liaison aux anticorps polypeptide mhc de classe 1 série a (mica)
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08873207

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010030486

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201011399

Country of ref document: CR

Ref document number: CR2010-011399

Country of ref document: CR

Ref document number: 2008873207

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载